Pharvaris (NASDAQ:PHVS) Sets New 52-Week High – Time to Buy?

Pharvaris N.V. (NASDAQ:PHVS)’s stock price hit a new 52-week high on Tuesday . The stock traded as high as $42.02 and last traded at $41.30, with a volume of 493228 shares changing hands. The stock had previously closed at $35.25.

Key Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris reported that its pivotal Phase 3 CHAPTER-3 trial of extended-release deucrictibant met its primary and all secondary efficacy endpoints, showing statistically significant and clinically meaningful prevention of HAE attacks. The results are intended to support regulatory applications planned to begin in the first half of 2027. Pharvaris CHAPTER-3 topline data
• Positive Sentiment: The CHAPTER-3 success, combined with earlier positive Phase 3 results for on-demand deucrictibant, strengthens Pharvaris’ potential to offer oral options for both prevention and treatment of HAE attacks. Analysts said the data could help the company capture market share in the HAE market. Pharvaris could gain HAE market share
• Positive Sentiment: RBC raised its price target to $62 from $52 and maintained an Outperform rating, while Citizens JMP increased its target to $79 from $75 with a Market Outperform rating. HC Wainwright also reaffirmed Buy with a $60 target, indicating broad analyst confidence in the program’s commercial potential.
• Positive Sentiment: A Seeking Alpha analysis maintained a “Strong Buy” view, citing the Phase 3 wins and the upcoming regulatory decision, or PDUFA event, for deucrictibant. Pharvaris Strong Buy analysis
• Neutral Sentiment: Despite the favorable data, Pharvaris remains a clinical-stage company. Regulatory approval, commercial execution, and the ability to compete with existing HAE therapies remain important uncertainties; RBC continued to characterize the stock as carrying speculative risk.
• Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The transaction may create a modest overhang, although it does not change the clinical outlook.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PHVS. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. Oppenheimer restated an “outperform” rating and set a $75.00 target price on shares of Pharvaris in a research note on Tuesday. New Street Research set a $60.00 price target on Pharvaris in a research note on Friday, August 14th. Wedbush set a $50.00 target price on Pharvaris and gave the company an “outperform” rating in a report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $59.21.

Pharvaris Price Performance

The firm has a market cap of $2.47 billion, a PE ratio of -12.37 and a beta of -2.33. The business has a 50-day simple moving average of $34.93 and a 200 day simple moving average of $31.27.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, equities analysts forecast that Pharvaris N.V. will post -3.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Anne Lesage sold 30,703 shares of Pharvaris stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the sale, the insider owned 93,969 shares in the company, valued at $3,334,959.81. This trade represents a 24.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the transaction, the director directly owned 315,167 shares in the company, valued at $11,185,276.83. This trade represents a 8.88% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 133,655 shares of company stock valued at $4,798,202. 11.84% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently bought and sold shares of PHVS. Quantbot Technologies LP purchased a new stake in Pharvaris in the 2nd quarter worth $41,000. CoreCap Advisors LLC bought a new position in Pharvaris during the second quarter valued at approximately $93,000. Barclays PLC purchased a new position in Pharvaris during the 4th quarter valued at approximately $77,000. JPMorgan Chase & Co. increased its position in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in Pharvaris during the fourth quarter valued at $139,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.